Hematologic Malignancy

A novel regimen significantly reduced risk for moderate to severe chronic graft-versus-host disease for certain patients who underwent allogeneic hematopoietic stem cell transplantation, according to randomized phase 2 study results.

A new retrospective analysis has added to building evidence that suggests chimeric antigen receptor T-cell therapy does not directly cause secondary malignancies.

The addition of itacitinib to standard graft-versus-host-disease prophylaxis may reduce severe toxicities following haploidentical hematopoietic stem cell transplantation, according to results of a single-arm study.

Jennifer A. Woyach, MD, has been named the new director of the division of hematology at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

Lee Greenberger, PhD, has retired as The Leukemia & Lymphoma Society’s chief scientific officer after more than a decade in the position.

A program designed to better meet the needs of adolescents and young adults with cancer helped ensure more of them had access to guideline-concordant care, according to study findings.

Ivan Maillard, MD, PhD, has been appointed head of the division of hematologic malignancies at Memorial Sloan Kettering Cancer Center.

Patients who used dupilumab for atopic dermatitis had significantly lower risks for internal malignancies than patients using other therapies, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Women diagnosed with a hematologic malignancy during pregnancy had a 22-fold higher rate of severe maternal morbidity than those who did not have blood cancer, according to study results.

Most cancer clinical trials use inaccurate tests to evaluate kidney function when determining participant eligibility, according to results of a cross-sectional study.